TheraVet: Positive Results of BIOCERA-VET®-Bone Surgery Presented at the Annual Conference of the US Veterinary Orthopedic Society and Confirmed on a Larger Patients Cohort

• Positive BIOCERA-VET^® arthrodesis data will be presented in collaboration with Dr. Guillaume Ragetly (ECVS, ACVS, PhD; France) at the US Veterinary Orthopedic Society
• The annual conference of US Veterinary Orthopedic Society, largest gathering of US orthopedic vet surgeons – is held conjointly this year with World Veterinary Orthopaedic Congress
• BIOCERA-VET^®-Bone Surgery confirmed as a valuable alternative to bone autograft on a larger patients cohort

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News:

TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces today the presentation in collaboration with Dr. Guillaume Ragetly (CHV Frégis, Paris, France) of BIOCERA-VET^® clinical data in bone fusion surgical procedure¹ at 6^th World Veterinary Orthopaedic Congress (WVOC) and 49^th Annual Conference of the Veterinary Orthopedic Society (VOS) 2022. Both conferences will be held conjointly from February 5^th to February 12^th, 2022 in Colorado, USA.

BIOCERA-VET^® clinical data² that will be presented on February 9^th , 2022 at the WVOC/VOS congress provide evidence of the equivalence of BIOCERA-VET^®-Bone Surgery with the autologous bone graft, the standard procedure in joint bone fusion. Indeed, an independent and blinded radiological evaluation assessing bone fusion in 13 canine cases of arthrodesis treated with BIOCERA-VET^® and in 16 cases treated with autologous bone graft³ showed that bone fusion induced by BIOCERA-VET^® at 4 and 8 weeks following surgery was as good as that induced by bone autograft, but with less complications (25% vs. 0%) and reduced surgical time by 30 to 45 min.

To confirm these clinical data, a larger cohort (doubling the number) of BIOCERA-VET^® treated-dogs⁴ have been assessed radiologically. This additional analysis demonstrated comparable bone fusion score of BIOCERA-VET^®-Bone surgery at 4 and 8 weeks with autologous bone graft (at 4 weeks, p>0.05 and at 8 weeks, p>0.05). Similar results were observed on carpal and tarsal bone fusions when analyzed separately. Excellent safety profile has also been confirmed.

These results therefore confirm the positioning of BIOCERA-VET^®-Bone Surgery as a valuable alternative to autologous bone graft in joint bone fusion.

About TheraVet SA

TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth^® Paris et Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the US.

For more information, visit the TheraVet
Or follow us on LinkedIn / Facebook / Twitter

_________________
¹ Arthrodesis
² Poster abstract: Efficacy and safety assessment of a self-setting bone substitute (α-TCP) as an efficient alternative to autografts. Ragetly G.R., Bouvy B., Flasse B., Stievenart O., Van Ommen J., Ragetly C.A.
³ all in addition to the standard surgical procedure
⁴ n= 20 vs n=10 at 4 weeks and n=27 vs n=13 at 8 weeks

TheraVet
Sabrina Ena
Chief Operating Officer
Sabrina.ena@thera.vet
Tel: +32 (0) 71 96 00 43

Julie Winand
Chief Corporate Officer
julie.winand@thera.vet

NewCap
Investor Relations and Financial Communications
Théo Martin / Olivier Bricaud
theravet@newcap.eu
Tel: +33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé / Ambre Delval
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15